Sobi publishes Q2 2023 report: Growth and pipeline expansion

Second quarter 2023 Second quarter 2023 Outlook 2023 - updated The outlook includes the newly acquired company CTI and Sobi's right to royalty on net sales of nirsevimab in the US. Investors, analysts and media are invited to participate in a conference call which will include a presentation of the results and a Q&A session at13:00 CEST. The presentation can be followed livehere  or afterwards on sobi.com. The slides will be made available on sobi.com prior to the...

Second quarter 2023

Outlook 2023 - updated

The outlook includes the newly acquired company CTI and Sobi's right to royalty on net sales of nirsevimab in the US.

Investors, analysts and media are invited to participate in a conference call which will include a presentation of the results and a Q&A session at 13:00 CEST.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.

To participate in the conference call, please use the following dial-in details:
Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06 13
United States: +1 631 570 56 13
For other countries, please get details here

Footnotes:
ⁱ  Excluding IAC.
ⁱⁱ  Alternative Performance Measures (APMs), see section APM for further information.
ⁱⁱⁱ Items affecting comparability (IAC), see page 3 for further information.

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East, Asia and Australia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.

Contact:
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, on 18 July 2023 at 08:00 CEST.

Jennifer Kretzmann
Manager of Stakeholder Communication and Corporate Access

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/sobi-publishes-q2-2023-report-growth-and-pipeline-expansion-301879481.html